Compare · GLS vs MRNA
GLS vs MRNA
Side-by-side comparison of Gelesis Holdings Inc. (GLS) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GLS and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $23.67B, about 69.3x GLS ($341.6M).
- MRNA has hit the wire 10 times in the past 4 weeks while GLS has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 0 for GLS).
- Company
- Gelesis Holdings Inc.
- Moderna Inc.
- Price
- $0.16-3.95%
- $59.69+0.34%
- Market cap
- $341.6M
- $23.67B
- 1M return
- -
- -6.63%
- 1Y return
- -
- +82.26%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 0
- 10
- Recent ratings
- 0
- 25
Gelesis Holdings Inc.
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest GLS
- Gelesis Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update, Financial Statements and Exhibits
- SEC Form CT ORDER filed by Gelesis Holdings Inc.
- SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)
- Gelesis Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form SC 13E3/A filed by Gelesis Holdings Inc. (Amendment)
- SEC Form PRER14A filed by Gelesis Holdings Inc.
- SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)
- SEC Form 4 filed by Puretech Health Plc
- Gelesis Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form SC 13E3/A filed by Gelesis Holdings Inc. (Amendment)
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester